Burlingame, United States
Halo Labs, founded in 2011, is making significant strides in the Analytics, Biopharma, Biotechnology, Health Care, and Pharmaceutical industries. The company, headquartered in the United States, positions itself as a leader in ensuring quality and safety in protein therapeutics and cell and gene therapy products.
With their slogan "Low Volume High-Throughput Cell, Gene, and Protein Therapeutic Quality," Halo Labs utilizes their flagship product, Aura, to revolutionize particle analysis. Aura offers a cutting-edge solution that combines the latest optics with innovative algorithms to analyze a wide range of biological samples. Its high-throughput and low-volume capabilities enhance quality control efficiency from pre-formulation stages onward.
In terms of financial growth, Halo Labs secured a $7.00M Series C investment on 11 July 2022, attracting prominent investors such as BioAdvance, BroadOak Capital Partners, RCT, and Agilent Technologies. This funding signals strong market confidence in their transformative approach to drug quality analytics.
Kinetic River Corp.
